BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Molina-Arcas M, Samani A, Downward J. Drugging the Undruggable: Advances on RAS Targeting in Cancer. Genes (Basel) 2021;12:899. [PMID: 34200676 DOI: 10.3390/genes12060899] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Cuesta C, Arévalo-Alameda C, Castellano E. The Importance of Being PI3K in the RAS Signaling Network. Genes (Basel) 2021;12:1094. [PMID: 34356110 DOI: 10.3390/genes12071094] [Reference Citation Analysis]
2 Zhou C, Fan Z, Zhou Z, Li Y, Cui R, Liu C, Zhou G, Diao X, Jiang H, Zheng M, Zhang S, Xu T. Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations. J Med Chem 2022. [PMID: 35230841 DOI: 10.1021/acs.jmedchem.1c01774] [Reference Citation Analysis]
3 Di Federico A, Tateo V, Parisi C, Formica F, Carloni R, Frega G, Rizzo A, Ricci D, Di Marco M, Palloni A, Brandi G. Hacking Pancreatic Cancer: Present and Future of Personalized Medicine. Pharmaceuticals (Basel) 2021;14:677. [PMID: 34358103 DOI: 10.3390/ph14070677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Vasta JD, Peacock DM, Zheng Q, Walker JA, Zhang Z, Zimprich CA, Thomas MR, Beck MT, Binkowski BF, Corona CR, Robers MB, Shokat KM. KRAS is vulnerable to reversible switch-II pocket engagement in cells. Nat Chem Biol. [DOI: 10.1038/s41589-022-00985-w] [Reference Citation Analysis]
5 Okafor C, Hogan J, Raygada M, Thomas BJ, Akshintala S, Glod JW, Del Rivero J. Update on Targeted Therapy in Medullary Thyroid Cancer. Front Endocrinol (Lausanne) 2021;12:708949. [PMID: 34489865 DOI: 10.3389/fendo.2021.708949] [Reference Citation Analysis]